Neurology / Multiple Sclerosis
Indication
Multiple Sclerosis
Assets addressing this indication.
Total attributable cost
$65.6B
$65,612/patient
Drug spend
$35.2B
$35,154/patient
54% of total cost is drugs
All US adult MS forms and disability strata (rounded prevalence context) · US